189 related articles for article (PubMed ID: 11985797)
1. Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity.
Sato N; Hattori Y; Wenlin D; Yamada T; Kamata T; Kakimoto T; Okamoto S; Kawamura C; Kizaki M; Shimada N; Ote Y; Hata J; Ikeda Y
Jpn J Cancer Res; 2002 Apr; 93(4):459-66. PubMed ID: 11985797
[TBL] [Abstract][Full Text] [Related]
2. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
5. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
6. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
Vacca A; Ribatti D; Presta M; Minischetti M; Iurlaro M; Ria R; Albini A; Bussolino F; Dammacco F
Blood; 1999 May; 93(9):3064-73. PubMed ID: 10216103
[TBL] [Abstract][Full Text] [Related]
8. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
Kumar S; Witzig TE; Timm M; Haug J; Wellik L; Kimlinger TK; Greipp PR; Rajkumar SV
Blood; 2004 Aug; 104(4):1159-65. PubMed ID: 15130943
[TBL] [Abstract][Full Text] [Related]
10. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow angiogenesis in patients with active multiple myeloma.
Vacca A; Ribatti D; Roccaro AM; Frigeri A; Dammacco F
Semin Oncol; 2001 Dec; 28(6):543-50. PubMed ID: 11740807
[TBL] [Abstract][Full Text] [Related]
12. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
13. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.
Scavelli C; Nico B; Cirulli T; Ria R; Di Pietro G; Mangieri D; Bacigalupo A; Mangialardi G; Coluccia AM; Caravita T; Molica S; Ribatti D; Dammacco F; Vacca A
Oncogene; 2008 Jan; 27(5):663-74. PubMed ID: 17667938
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma.
Vacca A; Ribatti D; Roccaro AM; Ria R; Palermo L; Dammacco F
Acta Haematol; 2001; 106(4):162-9. PubMed ID: 11815713
[TBL] [Abstract][Full Text] [Related]
15. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.
Saltarella I; Morabito F; Giuliani N; Terragna C; Omedè P; Palumbo A; Bringhen S; De Paoli L; Martino E; Larocca A; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Dammacco F; Boccadoro M; Vacca A; Ria R
J Hematol Oncol; 2019 Jan; 12(1):4. PubMed ID: 30626425
[TBL] [Abstract][Full Text] [Related]
16. [Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma].
Usnarska-Zubkiewicz L; Mazur G; Wróbel T; Poreba M; Kuliczkowski K
Pol Arch Med Wewn; 2003 Jul; 110(1):719-24. PubMed ID: 14682206
[TBL] [Abstract][Full Text] [Related]
17. Angiogenic activity of mesenchymal stem cells in multiple myeloma.
Wang X; Zhang Z; Yao C
Cancer Invest; 2011 Jan; 29(1):37-41. PubMed ID: 21166497
[TBL] [Abstract][Full Text] [Related]
18. [Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas].
Poreba M; Jaźwiec B; Kuliczkowski K; Poreba R
Pol Arch Med Wewn; 2005 Jan; 113(1):27-34. PubMed ID: 16130598
[TBL] [Abstract][Full Text] [Related]
19. Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation.
Greco C; Vitelli G; Vercillo G; Vona R; Giannarelli D; Sperduti I; Pisani F; Capoluongo E; Petti MC; Ameglio F
J Exp Clin Cancer Res; 2009 Mar; 28(1):35. PubMed ID: 19284554
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
Vacca A; Scavelli C; Montefusco V; Di Pietro G; Neri A; Mattioli M; Bicciato S; Nico B; Ribatti D; Dammacco F; Corradini P
J Clin Oncol; 2005 Aug; 23(23):5334-46. PubMed ID: 15939924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
